Last reviewed · How we verify
ACE inhibitor, angiotensin receptor blocker
At a glance
| Generic name | ACE inhibitor, angiotensin receptor blocker |
|---|---|
| Sponsor | Medical University Innsbruck |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria (PHASE3)
- The GUARDIAN Pilot Trial (NA)
- Focusing on the Menopausal Transition to Improve Mid-Life Women's Health (PHASE2, PHASE3)
- A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria (PHASE2)
- Exercise Rehabilitation for Cardiorenal Syndrome in HFrEF Patients (NA)
- Immune System in Diabetic Kidney Disease
- Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (PHASE4)
- Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection Fraction
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: